An Epidermal Microfluidic Screening Panel for Diabetes Mellitus Related Disorders

用于糖尿病相关疾病的表皮微流体筛查小组

• 批准号: 10252775
• 负责人: Tyler Ray
• 金额: $ 25.65万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10252775
• 关键词: Acute; Affect; Biochemical; Biochemical Markers; Biological Assay; Biological Markers; Biophysics; Cardiovascular Diseases; Centers of Research Excellence; Chronic Kidney Failure; Clinical assessments; Cognitive; Collection; Cystic Fibrosis; Diabetes Mellitus; Diagnostic; Disease; Disease Progression; Drug usage; Electrolytes; Fatigue; Glucose; Health; Health Status; Home; Hormones; Hypertension; Individual; Inflammatory; Intervention; Measurement; Mental Depression; Methods; Microfluidics; Monitor; Neuropathy; Non-Insulin-Dependent Diabetes Mellitus; Outcome; Pathology; Proteins; Standardization; Stress; System; Time; Work; comorbidity; eccrine; flexible electronics; improved; instrumentation; novel; patient population; screening panel; tool; wearable sensor technology

Diabetes Mellitus (DM) is a common, multifaceted condition affecting a vast number of individuals worldwide. Type-2 DM (T2D) comprises an estimated 90% of the patient population and is associated with substantial adverse health outcomes with the most important long-term DM-related disorders comprising chronic kidney disease (CKD), cardiovascular disease, and neuropathy and acute conditions such as ketoacidosis. The lack of facile diagnostic tools for the onset of DM-related comorbidities, particularly CKD and ketoacidosis, imposes intervention and treatment limitations. Although multiple biomolecular and biophysical markers have been proposed for DKD, ketoacidosis, and neuropathy, no standardized method or instrumentation currently exists. There is a critical need for improved measurement methods that will evaluate diabetes associated pathology in the home setting as easily as glucose is presently monitored. Here, the proposed work will develop a novel wearable system that integrates analysis of biochemical markers from eccrine sweat and biophysical activity sensing to establish a DM-relevant screening panel. Sweat contains a wealth of biomarkers relevant to health status, including electrolytes, metabolites, organic compounds, inflammatory/stress biomarkers, proteins and hormones. Aspects of sweat rate and composition have been used in assessing cystic fibrosis, drug use, physical fatigue, cognitive state, depression, and hypertension, among other conditions. This fully-integrated system represents a significant step towards improving the clinical assessment of the onset of DM-relevant complications and disease progression. The platform will house multi-use flexible electronics and a network of underlying microfluidic channels and biochemical assays for non-invasive collection and analysis of key sweat biomarkers. The microfluidics portion is a single use substrate that will have onboard colorimetric and electrochemical assays corresponding to identified bioanalytes for real-time analysis. The key biophysical and biochemical parameters monitored correspond to promising indicators of disease states for DKD, ketoacidosis, or neuropathy.

糖尿病 (DM) 是一种常见的、多方面的疾病，影响着全世界大量的人。 2 型糖尿病 (T2D) 约占患者群体的 90%，与严重的不良健康后果相关，其中包括最重要的长期 DM 相关疾病，包括慢性肾病 (CKD)、心血管疾病、神经病和酮症酸中毒等急性病症。由于缺乏针对 DM 相关合并症（特别是 CKD 和酮症酸中毒）发病的简便诊断工具，导致干预和治疗受到限制。尽管多种生物分子和生物物理标记物已被提出用于 DKD、酮症酸中毒和神经病，但目前尚不存在标准化方法或仪器。迫切需要改进的测量方法，能够像目前监测血糖一样轻松地在家中评估糖尿病相关病理。 在这里，拟议的工作将开发一种新型可穿戴系统，该系统集成了小汗腺汗液生化标记物分析和生物物理活动传感，以建立与糖尿病相关的筛查小组。汗液含有大量与健康状况相关的生物标志物，包括电解质、代谢物、有机化合物、炎症/压力生物标志物、蛋白质和激素。出汗率和成分已被用于评估囊性纤维化、药物使用、身体疲劳、认知状态、抑郁和高血压等疾病。这个完全集成的系统代表着朝着改善糖尿病相关并发症的发生和疾病进展的临床评估迈出了重要一步。该平台将容纳多用途柔性电子设备以及底层微流体通道和生化检测网络，用于非侵入性收集和分析关键汗液生物标记物。微流体部分是一次性基底，将具有与已识别的生物分析物相对应的板载比色和电化学测定，以进行实时分析。监测的关键生物物理和生化参数对应于 DKD、酮症酸中毒或神经病疾病状态的有希望的指标。